HONG KONG, CHINA--(Marketwired - December 14, 2016) - Hutchison China Meditech Limited (AIM: HCM) (NASDAQ: HCM)
Director's Share Dealing
London: Wednesday, December 14, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Mr Simon To, Executive Director and Chairman, purchased a total of 52,161 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med ("Ordinary Share")) at an average price of US$14.18 per ADS on December 9, 2016, December 12, 2016 and December 13, 2016.
Following the above purchase of 52,161 ADSs, Mr To is interested in 52,161 ADSs and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in a family trust of which his family members are the beneficiaries), representing approximately 0.34% of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
----------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------------
a)Name Mr Simon To
----------------------------------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a)Position/status Executive Director and Chairman
----------------------------------------------------------------------------
b)Initial Initial notification
notification/Amendment
----------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a)Name Hutchison China MediTech Limited
----------------------------------------------------------------------------
b)LEI N/A
----------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
----------------------------------------------------------------------------
a)Description of the ADS each representing one half of one Ordinary
financial instrument, type Share of US$1.00 ADS ISIN: US44842L1035
of instrument
Identification code
----------------------------------------------------------------------------
b)Nature of the transaction Acquisition of ADSs
----------------------------------------------------------------------------
c)Price(s) and volume(s)
----------------------------------------------
Price(s) Volume(s)
----------------------------------------------
US$14.05 10,000
----------------------------------------------
----------------------------------------------------------------------------
d)Aggregated information N/A
-Aggregated volume
-Price
----------------------------------------------------------------------------
e)Date of the transaction 2016-12-09
----------------------------------------------------------------------------
f)Place of the transaction Nasdaq Stock Market
----------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
----------------------------------------------------------------------------
a)Description of the ADS each representing one half of one Ordinary
financial instrument, type Share of US$1.00 ADS ISIN: US44842L1035
of instrument
Identification code
----------------------------------------------------------------------------
b)Nature of the transaction Acquisition of ADSs
----------------------------------------------------------------------------
c)Price(s) and volume(s)
----------------------------------------------
Price(s) Volume(s)
----------------------------------------------
US$14.12 30,000
----------------------------------------------
----------------------------------------------------------------------------
d)Aggregated information N/A
-Aggregated volume
-Price
----------------------------------------------------------------------------
e)Date of the transaction 2016-12-12
----------------------------------------------------------------------------
f)Place of the transaction Nasdaq Stock Market
----------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
----------------------------------------------------------------------------
a)Description of the ADS each representing one half of one Ordinary
financial instrument, type Share of US$1.00 ADS ISIN: US44842L1035
of instrument
Identification code
----------------------------------------------------------------------------
b)Nature of the transaction Acquisition of ADSs
----------------------------------------------------------------------------
c)Price(s) and volume(s)
----------------------------------------------
Price(s) Volume(s)
----------------------------------------------
US$14.43 12,161
----------------------------------------------
----------------------------------------------------------------------------
d)Aggregated information N/A
-Aggregated volume
-Price
----------------------------------------------------------------------------
e)Date of the transaction 2016-12-13
----------------------------------------------------------------------------
f)Place of the transaction Nasdaq Stock Market
----------------------------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.
Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.
Contacts
Investor Enquiries
Christian Hogg, CEO +852 2121 8200
International Media
Enquiries
Anthony Carlisle, +44 7973 611 888 anthony.carlisle@cdrconsultancy.co.uk
Citigate Dewe (Mobile)
Rogerson
U.S. Based Media
Enquiries
Brad Miles, BMC +1 (917) 570 7340 bmiles@bmccommunications.com
Communications (Mobile)
Susan Duffy, BMC +1 (917) 499 8887 sduffy@bmccommunications.com
Communications (Mobile)
Investor Relations
Matt Beck, The +1 (917) 415 1750 mbeck@troutgroup.com
Trout Group (Mobile)
David Dible, +44 7967 566 919 david.dible@citigatedr.co.uk
Citigate Dewe (Mobile)
Rogerson
Panmure Gordon (UK)
Limited
Richard Gray / +44 (20) 7886 2500
Andrew Potts
